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DEVELOPMENT

The Pharmacogene Variation (PharmVar)
Consortium: Incorporation of the Human
Cytochrome P450 (CYP) Allele Nomenclature
Database
Andrea Gaedigk1, Magnus Ingelman-Sundberg2, Neil A. Miller3, J. Steven Leeder1,
Michelle Whirl-Carrillo4, Teri E. Klein4 and the PharmVar Steering Committee
The Human Cytochrome P450 (CYP) Allele Nomenclature
Database, a critical resource for the pharmacogenetics and
genomics communities, has transitioned to the Pharmacogene
Variation (PharmVar) Consortium. In this report we provide a
summary of the current database, provide an overview of the
PharmVar consortium, and highlight the PharmVar database
which will serve as the new home for pharmacogene nomenclature.

THE HUMAN CYTOCHROME P450 (CYP) ALLELE
NOMENCLATURE DATABASE

An international group of leading experts in the emerging ﬁeld of
pharmacogenetics (PGx) came together in the mid 1990s to ﬁnd
a systematic way to catalog allelic variants of cytochrome P450
2D6 (CYP2D6).1 The proposed star (*) nomenclature system
provided the ﬁeld with a “common language” to name a growing
number of variants being discovered. Anticipating an explosion
of single nucleotide polymorphism (SNP) discovery for other
genes in the CYP superfamily involved in the metabolism of
xenobiotics, including many clinically used drugs, IngelmanSundberg et al. proposed to apply the general nomenclature rules
used for CYP2D6 to all other polymorphic CYP genes and eventually also cytochrome P450 oxidoreductase (POR).2 In 2002,
the Human Cytochrome P450 (CYP) Allele Nomenclature
Database (“Nomenclature website” for short) and Committee
was established to systematically classify an increasing number of
CYP allelic variants.3 The star (*) nomenclature was readily
embraced by the pharmacogenetics ﬁeld and the Nomenclature
website was swiftly accepted as the central hub for CYP allele definition. The Nomenclature website has been maintained at the

Karolinska Institutet under the leadership of Magnus IngelmanSundberg since its inception at http://www.cypalleles.ki.se/.4
Being the leading authority for P450 nomenclature, PGx experts
rely heavily on the catalog of haplotype deﬁnitions listed on the
Nomenclature website for basic and translational research as well
as many clinical applications including genotype test reporting.
One prominent example is the Clinical Pharmacogenetic Implementation Consortium (CPIC), which facilitates the use of pharmacogenetic tests for patient care by creating freely available
evidence-based gene/drug clinical practice guidelines (https://
cpicpgx.org/). The CPIC utilizes allele designations as deﬁned by
the Nomenclature website. The Pharmacogenomics Knowledge
Base (PharmGKB; https://www.pharmgkb.org), a leading pharmacogenomics knowledge resource, also relies on the Nomenclature website for CYP allele deﬁnitions. Standardized allele
deﬁnitions are also integral to the development of bioinformatic
tools to automate the assignment of star allele genotypes from
multiple genotyping platforms, including panels, array platforms,
and Next-Generation Sequencing. Examples include the Pharmacogenomic Clinical Annotation Tool (PharmCAT), which takes
genomic data to make haplotype calls and get CPIC annotations
(https://www.pharmgkb.org/page/pharmcat); Astrolabe, a tool
developed to assign CYP2D6 genotype from Whole Genome
Sequence data (currently expanded to CYPs 2C9 and 19)5; or tools
that are integrated into commercial array analysis algorithms, such
as the DMET and PharmacoScan Console Software packages.
Needless to say, the Nomenclature website has become an
integral part of pharmacogenetics over the years as it has established itself as the authority for issuing and maintaining allele
designations.
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Figure 1 The Human Cytochrome P450 (CYP) Allele Nomenclature Database has transitioned to the Pharmacogene Variation Consortium (PharmVar).
PharmVar will closely work with the PharmGKB for data curation and dissemination.

After dedicating many years of his distinguished career to
developing and maintaining the CYP Allele Nomenclature
resource together with Sarah Sim, who served as the Webmaster
for 12 years, both Magnus Ingelman-Sundberg and Sarah Sim
have retired from the nomenclature site to focus on other projects. This resource has provided an invaluable service to the drug
metabolism and PGx communities, and would be a critical loss to
these communities should it cease to exist. Therefore, a group of
stakeholders came together to develop a plan to maintain and
sustain what was unanimously agreed on to be an essential
resource. By the same token, the group also identiﬁed a number
of limitations and opportunities to raise pharmacogene variation
to a new level. To that end, the PharmVar Steering Committee
consisting of 19 members representing academia, clinical, and
commercial interests was assembled to discuss a path forward.
Over the past year a series of teleconferences were organized
under the leadership of Andrea Gaedigk, Steve Leeder, and Teri
Klein, and in May of 2017 a Face-to-Face meeting was held at
Children’s Mercy Kansas City to discuss “must-have” features of
a future database, revisions to the nomenclature system itself, a
standardized and transparent submission process and allele designation. Furthermore, mechanisms for ﬁnancial support were discussed, including seeking National Institutes of Health (NIH)
funding to support the development of a “Next-Generation” pharmacogene database operated through a consortium model, the
Pharmacogene Variation (PharmVar) Consortium.
THE PHARMACOGENE VARIATION (PHARMVAR)
CONSORTIUM

The PharmVar Consortium will serve as the new hub for pharmacogene nomenclature. As a ﬁrst step, the Human Cytochrome P450
(CYP) Allele Nomenclature Database has transitioned to Children’s
Mercy Kansas City from its current location at the Karolinska
Institutet in Sweden, on September 26, 2017 (Figure 1). The
PharmVar database will be an interactive state-of-the art database
2

and serve as a centralized “Next-Generation” Pharmacogene Variation data repository. The inaugural version, to be launched in early
2018, will be kick-started with three high-priority genes, CYP2C9,
CYP2C19, and CYP2D6. Over the course of the ﬁrst year of the
project all other CYP genes that have been housed by the Nomenclature website will be transferred into the PharmVar database.
Once a gene is transferred, it will no longer be updated on the
Nomenclature website pages (a link through PharmVar will allow
continued access to a “legacy” version). As the PharmVar database
grows, other PGx genes will be added to the PharmVar database in
the future. Of particular interest will be clinically actionable genes
such as DPYD and SLCO1B1, for which the CPIC is publishing
dosing guidelines and for which no systematic nomenclature exists.
PharmVar will not be limited to genes involved in drug metabolism,
and plans to eventually also house genes contributing to drug transport and response.
The PharmVar Consortium, operating as a Pharmacogenetic
Research Network (http://www.pgrn.org/pharmvar.html) resource,
invites experts with an interest in PGx variation to become a
PharmVar community member. The PharmVar database will accept
submissions from research, clinical, and commercial laboratories
following a standardized submission protocol and criteria (forms are
available at www.PharmVar.org).
In addition to a transparent submission and review process, the
PharmVar database will assign unique version numbers to haplotype deﬁnitions, genes, and database releases to enable robust tracking of nomenclature data and simplifying the task of determining
the exact allele deﬁnitions used in a particular analysis. All variants
will consistently be linked to rs numbers/dbSNP identiﬁers, if
available, and the user will be able to list all alleles carrying a particular SNP of interest. The database will also include a number of
other functional features, including the generation of customizable
tables of genes or gene regions of interest, sequence alignments,
and have the option of downloading variant sequences, among
other features. Information regarding the functional consequences
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Figure 2 Overview of the Pharmacogene Variation Consortium.

of allelic variation will be added in the future and synchronized
with PharmGKB and CPIC annotations through direct communication with these collaborating groups. Allelic variants will be
mapped to a gene’s most recent RefSeqGene sequence, to its Locus
Reference Genomic sequence (LRG, a stable genomic framework
that never changes), and to the human Reference Genome Builds
GRCh37/hg19 and GRCh38/hg38 for easy referencing across
numbering systems. For many of the CYP genes listed on the
Nomenclature website, the reference sequence used to deﬁne allelic
variation does not match the RefSeqGene. Among those are
CYP2D6, which is annotated using M33388 and not the
NG_008376.3 RefSeq, or CYP2B6 and CYP3A5, which are
mapped to RefSeq records that have been removed by the NCBI.
In these cases, legacy numbering will be provided to facilitate crossreferencing. Of note, some allele deﬁnitions will require revision.
For instance, for CYP2D6 SNP coordinates past 1 600 will shift
due to a 1-bp gain and two 1-bp losses distinguishing M33388
from the gene’s NG_008376.3 RefSeq. Accordingly, the SNP
deﬁning CYP2D6*4 will be shown as 1847G>A when mapped to
NG_008376.3. Although these revisions may require updating on,
e.g., test reports, standardized mapping of allelic variation is a prerequisite to facilitating genomic data analysis, automated pipelines,
and standardized reporting.
In addition to being a searchable database, PharmVar will also
offer a number of graphical display functions, including comparisons of user-selected sequences and the assembly of custom tables
showing genes or gene regions for SNPs of interest. In addition
to content displayed on the website, PharmVar will provide a
capability for bulk data downloads as well as an Application
Programming Interface (API) to enable programmatic access to
database content.
The PharmVar database will be a user-friendly resource for
pharmacogene variation data and directly accessible to all users
(requests for allele designations will, however, require a user
account). PharmVar will coordinate its efforts with the
PharmGKB as well as other stakeholders such as the CPIC to
provide uniﬁed and standardized pharmacogene variation
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designation and information regarding translation into phenotype to the PGx community. Coordinated efforts with the
PharmGKB will include, for instance, the curation of variants
and their incorporation into the annotations on the PharmGKB
and deposit variants as part of their regular submissions to ClinVar. The PharmVar Consortium with its rich expertise and close
collaborations with the PharmGKB and CPIC is uniquely positioned to contribute to the advancement of genome-informed
medicine and PGx-guided individualized drug therapy at large.
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